Drug Search Results
More Filters [+]

Labradimil

Alternative Names: labradimil, lobradimil, cereport, rmp-7
Latest Update: 2020-09-18
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: B2 Agonist

Novel Mechanism: Yes

Modality: Large Molecule

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Alkermes
Company Location: DUBLIN 4 L2 00000
Company CEO: Richard F. Pops
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Labradimil

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Brain Stem Cancer

Phase 1: Glioma|Brain Stem Cancer|Meningitis, Cryptococcal|Medulloblastoma|HIV Infections|Acquired Immunodeficiency Syndrome

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

ADVL0012

P1

Completed

Glioma|Brain Stem Cancer

2005-01-01

96-C-0068

P1

Completed

Glioma|Medulloblastoma

None

131A

P1

Completed

Meningitis, Cryptococcal|HIV Infections|Acquired Immunodeficiency Syndrome

None

CDR0000066169

P2

Completed

Brain Stem Cancer

None

Recent News Events